Clinical Trial Update: Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating masitinib in combination with standard of care versus placebo for amyotrophic lateral sclerosis; the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Status: NOT_YET_RECRUITING